Newborn affected by other maternal noxious substances
ICD-10 P04.89 is a billable code used to indicate a diagnosis of newborn affected by other maternal noxious substances.
P04.89 is used to classify newborns who are affected by maternal exposure to noxious substances, which can include drugs, alcohol, and tobacco, transmitted through the placenta or breast milk. This condition encompasses a range of potential effects on the newborn, including withdrawal symptoms, developmental delays, and other health complications. Maternal drug use, particularly opioids, can lead to neonatal abstinence syndrome (NAS), characterized by irritability, feeding difficulties, and seizures. Alcohol exposure can result in fetal alcohol spectrum disorders (FASD), which may manifest as growth deficiencies and neurodevelopmental issues. Tobacco use during pregnancy is associated with low birth weight and respiratory problems in newborns. Accurate coding requires thorough documentation of maternal substance use, the timing of exposure, and the specific effects observed in the newborn. This code is essential for tracking the impact of maternal health behaviors on neonatal outcomes and for ensuring appropriate care and resources are allocated to affected infants.
Detailed maternal history, including substance use patterns, timing of exposure, and newborn assessment findings.
Newborns presenting with withdrawal symptoms in the NICU, infants with FASD being monitored for developmental milestones.
Consider the need for interdisciplinary collaboration with social services and addiction specialists.
Ongoing assessment of developmental milestones and health outcomes related to maternal substance exposure.
Pediatric follow-up for infants with known maternal substance exposure, monitoring for growth and behavioral issues.
Awareness of long-term effects of maternal substance use on child development.
Used for the initial evaluation of a newborn affected by maternal substance use.
Document maternal history, newborn assessment findings, and any interventions required.
Neonatologists should ensure comprehensive documentation to support the diagnosis.
To support the use of P04.89, coders need detailed documentation of maternal substance use, including the type of substances, timing of exposure, and any observed effects on the newborn. Clinical assessments and follow-up evaluations should also be documented to provide a comprehensive view of the infant's condition.
